{"entity":{"id":"nct07389265","kind":"trial","name":"Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer","aka":["CAPRI-3 GOIM"],"tldr":"A phase 3 trial of cetuximab, bevacizumab (glioblastoma use), fOLFOX (5-FU, leucovorin, oxaliplatin) and fOLFIRI (5-FU, leucovorin, irinotecan) in colorectal cancer, run by University of Campania Luigi Vanvitelli, now recruiting.","summary":"Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer is a phase 3, randomised interventional study registered as NCT07389265 by University of Campania Luigi Vanvitelli, with a registry enrolment figure of 480 participants, started 2025-10-01 and due to reach its primary completion in 2030-10. Interventions recorded: Erbitux (Cetuximab); Bevacizumab; FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin); FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan). Conditions listed: Metastatic Colorectal Cancer (mCRC). Primary outcome: Overall Response Rate (ORR). Colorectal eligibility wording from the registry: \"Histologically proven diagnosis of colorectal adenocarcinoma\". Sites: Italy, Spain. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07389265","url":"https://clinicaltrials.gov/study/NCT07389265"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["cytotoxic-chemotherapy","monoclonal-antibody","platinum","topoisomerase-inhibitors"],"targets":[],"drugs":["cetuximab","bevacizumab-glioma","folfox","folfiri"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07389265","phase":"3","setting":"CAPRI-3 GOIM Study: Phase 3 Clinical Study to Evaluate the Use of Continuing Cetuximab Treatment Beyond First Line Progression in Molecular Selected Metastatic Colorectal Cancer Patients.","sponsor":"University of Campania Luigi Vanvitelli","enrolled":480,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07389265/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/"},{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/"},{"id":"folfiri","kind":"drug","name":"FOLFIRI (5-FU, leucovorin, irinotecan)","route":"/drugs/folfiri/"},{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}